Two Monoclonal Antibody Drugs Are Rendered Useless by Omicron
By Radiant HealthPublished: January 30, 2022
The FDA has decided to restrict the use of two types of monoclonal antibody treatments. The drugs were previously made available in the U.S. because they were effective against other variants of Covid-19, but research shows that they do little to work against the Omicron variant. At this point, 99% of all positive cases in the country are due to the Omicron variant, so the drugs serve no purpose. The only monoclonal antibody treatment that has been approved for use against Omicron, sotrovimab, is available in very few places in the country.
Like what you're reading? Sign up for our free newsletter and never miss a post! Plus get a FREE digital version of our Issue No.10 with sign up.
- 11 Best Health and Wellness Books to Read in 2024 - July 4, 2024
- Some Americans Will Have Medical Debt Wiped From Credit - July 9, 2022
- Natural Gas Used to Heat Homes Contains Some Harmful Chemicals - July 9, 2022
- Uterine Cancer Claims Many Black Lives - July 9, 2022
- Babies and Toddlers Get COVID-19 Shots - June 27, 2022
- FDA Bans Juul’s E-Cigarettes and Cartridges - June 27, 2022
- Polio Virus Found in London Sewage - June 27, 2022
- 200 Million Americans Are Drinking Contaminated Water - June 19, 2022
- Young Kids Can Finally Get Vaccinated Against COVID-19 - June 19, 2022
- New Regulations for Baby Sleep Products - June 19, 2022